CORT Corcept Therapeutics Incorporated

+0.31  (+3%)
Previous Close 11.09
Open 11.1
Price To Book 5.07
Market Cap 1316378497
Shares 115,471,798
Volume 1,124,611
Short Ratio
Av. Daily Volume 2,169,952

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved February 17, 2012.
Corlux - Korlym
Cushing's Syndrome
Phase 2 ongoing.
Mifepristone plus enzalutamide
Castration-resistant prostate cancer (CRPC)
Phase 1/2 data released December 10, 2016 - 4/21 partial responses.
Mifepristone in combination with eribulin
Cancer - triple-negative breast cancer
Phase 2 pancreatic data due 1Q 2019.
Solid tumors - cancer
Phase 3 commencement of enrolment announced November 19, 2018.
Cushing’s syndrome
Phase 2 trial to commence later in 2018.
Relacorilant plus Abraxane
Ovarian cancer

Latest News

  1. Corcept Therapeutics To Announce Audited Financial Results, Provide Corporate Update And Host Conference Call
  2. Glancy Prongay & Murray LLP Announces Investigation on Behalf of Corcept Therapeutics Incorporated Investors
  3. Recent Analysis Shows Corcept Therapeutics, CDK Global, Dynavax Technologies, ICU Medical, American Vanguard, and Cabot Market Influences — Renewed Outlook, Key Drivers of Growth
  4. Options Traders Expect Huge Moves in Corcept (CORT) Stock
  5. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Corcept Therapeutics Incorporated Investors
  6. Investors Are Undervaluing Corcept Therapeutics Incorporated (NASDAQ:CORT) By 49.63%
  7. Investor Alert: Kaplan Fox Investigates Corcept Therapeutics Incorporated
  8. Puts Pop Amid Drug Stock's Roller-Coaster Session
  9. Here's Why Corcept Therapeutics Fell as Much as 13.7% Today
  10. Corcept Therapeutics Announces Fourth Quarter and Full-Year 2018 Preliminary Selected Financial Results; Provides 2019 Revenue Guidance
  11. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Corcept Therapeutics Incorporated
  12. Here's Why Corcept Therapeutics Stock Fell as Much as 18.5% Today
  13. Corcept Puts Active After Negative Report
  14. Can Corcept Therapeutics Incorporated (NASDAQ:CORT) Maintain Its Strong Returns?
  15. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
  16. Is Corcept Therapeutics Incorporated (CORT) A Good Stock To Buy?
  17. Biotech Companies in the News
  18. IBD 50 Stocks To Watch: Corcept Expected To Pick Up Growth In 2019